Suppr超能文献

与重组DNA预激发联合时,gp120蛋白的免疫原性增强,可产生中和1型人类免疫缺陷病毒JR-FL原始分离株的抗体。

Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.

作者信息

Wang Shixia, Arthos James, Lawrence John M, Van Ryk Donald, Mboudjeka Innocent, Shen Siyuan, Chou Te-Hui W, Montefiori David C, Lu Shan

机构信息

Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605-2397, USA.

出版信息

J Virol. 2005 Jun;79(12):7933-7. doi: 10.1128/JVI.79.12.7933-7937.2005.

Abstract

Strategies are needed for human immunodeficiency virus type 1 vaccine development that improves the neutralizing antibody response against primary isolates of the virus. Here we examined recombinant DNA priming followed by subunit protein boosting as a strategy to generate neutralizing antibodies. Both plasmid-based and recombinant protein envelope (Env) glycoprotein immunogens were derived from a primary viral isolate, JR-FL. Serum from rabbits immunized with either gp120 or gp140 DNA vaccines delivered by gene gun inoculation followed by recombinant gp120 protein boosting was capable of neutralizing JR-FL. Neither the DNA vaccines alone nor the gp120 protein alone generated a detectable neutralizing antibody response against this virus. Neutralizing antibody responses using gp120 DNA and gp140 DNA for priming were similar. The results suggest that Env DNA priming followed by gp120 protein boosting provides an advantage over either approach alone for generating a detectable neutralizing antibody response against primary isolates that are not easily neutralized.

摘要

需要制定策略来开发1型人类免疫缺陷病毒疫苗,以增强针对该病毒原始分离株的中和抗体反应。在此,我们研究了先进行重组DNA初免,然后进行亚单位蛋白加强免疫,以此作为产生中和抗体的一种策略。基于质粒的免疫原和重组蛋白包膜(Env)糖蛋白免疫原均来源于一株原始病毒分离株JR-FL。用基因枪接种gp120或gp140 DNA疫苗进行初免,随后用重组gp120蛋白进行加强免疫的兔子血清能够中和JR-FL。单独的DNA疫苗或单独的gp120蛋白均未产生针对该病毒的可检测到的中和抗体反应。使用gp120 DNA和gp140 DNA进行初免所产生的中和抗体反应相似。结果表明,与单独使用任何一种方法相比,先进行Env DNA初免,然后进行gp120蛋白加强免疫,在针对不易被中和的原始分离株产生可检测到的中和抗体反应方面具有优势。

相似文献

8
Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
AIDS Res Hum Retroviruses. 2004 Nov;20(11):1259-68. doi: 10.1089/aid.2004.20.1259.

引用本文的文献

2
A broad-spectrum multiepitope vaccine against seasonal influenza A and B viruses in mice.
EBioMedicine. 2024 Aug;106:105269. doi: 10.1016/j.ebiom.2024.105269. Epub 2024 Aug 6.
3
Development of an RBD-Fc fusion vaccine for COVID-19.
Vaccine X. 2024 Jan 21;16:100444. doi: 10.1016/j.jvacx.2024.100444. eCollection 2024 Jan.
4
Mixed formulation of mRNA and protein-based COVID-19 vaccines triggered superior neutralizing antibody responses.
MedComm (2020). 2022 Dec 2;3(4):e188. doi: 10.1002/mco2.188. eCollection 2022 Dec.
5
Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review.
Infect Dis Rep. 2022 Jul 20;14(4):537-546. doi: 10.3390/idr14040057.
7
Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
Emerg Microbes Infect. 2021 Dec;10(1):1598-1608. doi: 10.1080/22221751.2021.1957401.
8
DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses.
Emerg Microbes Infect. 2021 Dec;10(1):833-841. doi: 10.1080/22221751.2021.1918026.
9
Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates.
Emerg Microbes Infect. 2021 Dec;10(1):629-637. doi: 10.1080/22221751.2021.1902245.

本文引用的文献

1
Antigen engineering in DNA immunization.
Methods Mol Med. 2000;29:355-74. doi: 10.1385/1-59259-688-6:355.
2
Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays.
Curr Protoc Immunol. 2005 Jan;Chapter 12:12.11.1-12.11.17. doi: 10.1002/0471142735.im1211s64.
3
Urgently needed: a filter for the HIV-1 vaccine pipeline.
Nat Med. 2004 Aug;10(8):769-71. doi: 10.1038/nm0804-769.
4
Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen.
AIDS. 2004 Apr 30;18(7):991-1001. doi: 10.1097/00002030-200404300-00006.
5
HIV vaccine design and the neutralizing antibody problem.
Nat Immunol. 2004 Mar;5(3):233-6. doi: 10.1038/ni0304-233.
6
HIV vaccines 1983-2003.
Nat Med. 2003 Jul;9(7):874-80. doi: 10.1038/nm0703-874.
7
Immunopathogenesis and immunotherapy in AIDS virus infections.
Nat Med. 2003 Jul;9(7):861-6. doi: 10.1038/nm0703-861.
8
Antibody neutralization and escape by HIV-1.
Nature. 2003 Mar 20;422(6929):307-12. doi: 10.1038/nature01470.
9
Prospects for vaccine protection against HIV-1 infection and AIDS.
Annu Rev Immunol. 2002;20:73-99. doi: 10.1146/annurev.immunol.20.081501.094854. Epub 2001 Oct 4.
10
Vaccines for the prevention of HIV-1 disease.
Curr Opin Immunol. 2001 Aug;13(4):489-95. doi: 10.1016/s0952-7915(00)00246-6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验